Skip to content

Study · Randomized controlled trial · n = 10 · 2012

4 results

Intranasal oxytocin administration is reflected in human saliva.

Weisman O, Zagoory-Sharon O, Feldman R

Psychoneuroendocrinology20 Mar 2012Cited by 86 (Europe PMC)

PMID22436536 (opens in a new tab)DOI10.1016/j.psyneuen.2012.02.014 (opens in a new tab)PepBankPUB-22436536
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialPharmacokinetics

    In ten individuals, intranasal oxytocin induced substantial increases in salivary oxytocin across the whole 4-hour period compared with placebo.

    In plain wordsIn ten people, oxytocin spray raised oxytocin levels in saliva for the whole four hours, compared with placebo.

    Peptide
    Oxytocin
    Outcome
    IncreaseSalivary oxytocin over 4 hours
    Study

    n = 10

    Comparator
    Placebo
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · intranasalAs given in this study (human).

    Source sentences

    Summary
    OT administration induced substantial increases in salivary OT across the entire period.
    1 context sentence
    Summary · context
    Utilizing a double-blind placebo-control within-subject design, ten individuals were administered OT or placebo and salivary OT was measured ten times, at baseline and nine times over four consecutive hours.
  2. 02HumanRandomized controlled trialPharmacokinetics

    In ten individuals, salivary oxytocin rose from 6.9 pg/ml at baseline to 1265.4 pg/ml 15 min after intranasal oxytocin.

    In plain wordsIn ten people, oxytocin in saliva rose very fast, 15 minutes after the spray.

    Peptide
    Oxytocin
    Outcome
    IncreaseSalivary oxytocin at 15 min
    Study

    n = 10

    Comparator
    Baseline (before administration)
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · intranasalAs given in this study (human).

    Measurements

    Salivary OT
    6.9 pg/ml
    baseline
    Salivary OT
    1265.4 pg/ml
    15 min after administration

    Source sentences

    Summary
    OT rose dramatically 15 min after administration (from 6.9 pg/ml at baseline to 1265.4 pg/ml
    1 context sentence
    Summary · context
    Utilizing a double-blind placebo-control within-subject design, ten individuals were administered OT or placebo and salivary OT was measured ten times, at baseline and nine times over four consecutive hours.
  3. 03HumanRandomized controlled trialPharmacokinetics

    In ten individuals, salivary oxytocin reached a plateau at 45-120 min after intranasal oxytocin.

    In plain wordsIn ten people, oxytocin in saliva stayed on a plateau from 45 to 120 minutes after the spray.

    Peptide
    Oxytocin
    Outcome
    IncreaseSalivary oxytocin plateau at 45-120 min
    Study

    n = 10

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · intranasalAs given in this study (human).

    Measurements

    Salivary OT plateau
    131.6 pg/ml
    45-120 min
    Salivary OT plateau
    105.3 pg/ml
    45-120 min

    Source sentences

    Summary
    reached plateau at 45-120 min (range=131.6 and 105.3 pg/ml
    1 context sentence
    Summary · context
    Utilizing a double-blind placebo-control within-subject design, ten individuals were administered OT or placebo and salivary OT was measured ten times, at baseline and nine times over four consecutive hours.
  4. 04HumanRandomized controlled trialPharmacokinetics

    In ten individuals, salivary oxytocin had not returned to baseline by 4 hours after intranasal oxytocin.

    In plain wordsIn ten people, oxytocin in saliva was still above the starting level four hours after the spray.

    Peptide
    Oxytocin
    Outcome
    IncreaseSalivary oxytocin at 4 hours versus baseline
    Study

    n = 10

    Comparator
    Baseline (before administration)
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · intranasalAs given in this study (human).

    Source sentences

    Summary
    and did not return to baseline by 4h.
    1 context sentence
    Summary · context
    Utilizing a double-blind placebo-control within-subject design, ten individuals were administered OT or placebo and salivary OT was measured ten times, at baseline and nine times over four consecutive hours.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 01:30 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.